How Real-World Evidence is Impacting Regulatory Decision-Making: A Collection of 12 Recent Approvals Based on RWE
Volume 1 From the new FDA framework to the urgency of COVID-19, recent events have dramatically accelerated the use of RWE in regulatory decision-making. Now, life sciences organizations are investing heavily in analytics to generate RWE for regulatory submission.
RWE: Supporting Regulatory Submissions with Real-World Evidence
When submitting RWE, it is crucial for life sciences organizations to not only feel confident in the data they provide, but also that it will be accepted by regulatory reviewers, writes Panalgo’s Tiffany Siu Woodworth. The main question these companies must ask themselves is, how can we trust the evidence we are providing?
